Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8546143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of a target gene |
Jan, 2022
(2 years ago) | |
US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(3 months ago) | |
US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(a month ago) | |
US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(a month ago) | |
US11530408 | ALNYLAM PHARMS INC | Therapeutic compositions |
May, 2024
(19 days from now) | |
US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(1 year, 3 months from now) | |
US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(4 years from now) | |
US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(5 years from now) | |
US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) | |
US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Nov, 2033
(9 years from now) | |
US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(10 years from now) | |
US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) |
Givlaari is owned by Alnylam Pharms Inc.
Givlaari contains Givosiran Sodium.
Givlaari has a total of 14 drug patents out of which 4 drug patents have expired.
Expired drug patents of Givlaari are:
Givlaari was authorised for market use on 20 November, 2019.
Givlaari is available in solution;subcutaneous dosage forms.
Givlaari can be used as treatment of acute hepatic porphyria.
Drug patent challenges can be filed against Givlaari from 21 November, 2023.
The generics of Givlaari are possible to be released after 03 October, 2034.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS